Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT
Identifieur interne : 000656 ( Main/Repository ); précédent : 000655; suivant : 000657Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT
Auteurs : RBID : Pascal:13-0258536Descripteurs français
- Pascal (Inist)
- Méthode non invasive, Metalloendopeptidases, Cible, Ciblage, Tomographie par émission de positons, Tomoscintigraphie émission monophotonique, Produit radioisotopique, Inhibiteur enzyme, Peptide, Article synthèse, Marquage radioisotopique, Technétium 99mTc, Indium 111, Iode 123, Fluor 18, Imagerie moléculaire.
English descriptors
- KwdEn :
Abstract
Dysregulation of matrix metalloproteinase (MMP) activity can lead to a wide range of disease states such as atherosclerosis, inflammation or cancer. The ability to image MMP activity non-invasively in vivo, by radiolabelled synthetic inhibitors, would allow the characterization of atherosclerotic plaques, inflammatory lesions or tumors. Here we present an overview of radiolabelled MMP inhibitors (MMPIs) and MMP peptides for positron emission tomography (PET) and single photon emission computed tomography (SPECT) for the detection of proteolytic activity of MMPs. So far, most studies are at a preliminary stage; however, some hydroxamate-based tracers such as the peptidomimetics [111In]-DTPA-RP782, [99mTc]-(HYNIC-RP805)(tricine)(TPPTS), or Marimastat-ArB[18F]F3 and the picolyl-benzenesulfonamide [123I]I-HO-CGS 27023A identified specifically the enzymatic action of MMPs in animal models of various pathologies. The development of new compounds that may lead to novel tracers (e.g. modification of zinc-binding group, variation of substituents attached to the S1', S2' and S3' pockets of the MMP inhibitors) and the use of antibodies and cell penetrating peptides are also discussed. In general, preclinical studies with atherosclerosis models proved to be more successful than those with oncological models.
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 000959
Links to Exploration step
Pascal:13-0258536Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT</title><author><name sortKey="Matusiak, Nathalie" uniqKey="Matusiak N">Nathalie Matusiak</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue (ville)</settlement><region>Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author><author><name sortKey="Van Waarde, Aren" uniqKey="Van Waarde A">Aren Van Waarde</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue (ville)</settlement><region>Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author><author><name sortKey="Bischoff, Rainer" uniqKey="Bischoff R">Rainer Bischoff</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>3 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue (ville)</settlement><region>Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author><author><name sortKey="Oltenfreiter, Ruth" uniqKey="Oltenfreiter R">Ruth Oltenfreiter</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Nuclear Medicine, University Hospital Ghent, University of Ghent</s1><s2>Ghent</s2><s3>BEL</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Van De Wiele, Christophe" uniqKey="Van De Wiele C">Christophe Van De Wiele</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Nuclear Medicine, University Hospital Ghent, University of Ghent</s1><s2>Ghent</s2><s3>BEL</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Dierckx, Rudi A J O" uniqKey="Dierckx R">Rudi A. J. O Dierckx</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue (ville)</settlement><region>Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Nuclear Medicine, University Hospital Ghent, University of Ghent</s1><s2>Ghent</s2><s3>BEL</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author><author><name sortKey="Elsinga, Philip H" uniqKey="Elsinga P">Philip H. Elsinga</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue (ville)</settlement><region>Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Nuclear Medicine, University Hospital Ghent, University of Ghent</s1><s2>Ghent</s2><s3>BEL</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Ghent</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="inist">13-0258536</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0258536 INIST</idno><idno type="RBID">Pascal:13-0258536</idno><idno type="wicri:Area/Main/Corpus">000959</idno><idno type="wicri:Area/Main/Repository">000656</idno></publicationStmt><seriesStmt><idno type="ISSN">1381-6128</idno><title level="j" type="abbreviated">Curr. pharm. des. : (Print)</title><title level="j" type="main">Current pharmaceutical design : (Print)</title></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Enzyme inhibitor</term><term>Metalloendopeptidases</term><term>Molecular imaging</term><term>Non invasive method</term><term>Peptides</term><term>Positron emission tomography</term><term>Radioisotopic product</term><term>Radiolabelling</term><term>Review</term><term>Single photon emission tomography</term><term>Target</term><term>Targeting</term><term>Technetium 99mTc</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Méthode non invasive</term><term>Metalloendopeptidases</term><term>Cible</term><term>Ciblage</term><term>Tomographie par émission de positons</term><term>Tomoscintigraphie émission monophotonique</term><term>Produit radioisotopique</term><term>Inhibiteur enzyme</term><term>Peptide</term><term>Article synthèse</term><term>Marquage radioisotopique</term><term>Technétium 99mTc</term><term>Indium 111</term><term>Iode 123</term><term>Fluor 18</term><term>Imagerie moléculaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dysregulation of matrix metalloproteinase (MMP) activity can lead to a wide range of disease states such as atherosclerosis, inflammation or cancer. The ability to image MMP activity non-invasively in vivo, by radiolabelled synthetic inhibitors, would allow the characterization of atherosclerotic plaques, inflammatory lesions or tumors. Here we present an overview of radiolabelled MMP inhibitors (MMPIs) and MMP peptides for positron emission tomography (PET) and single photon emission computed tomography (SPECT) for the detection of proteolytic activity of MMPs. So far, most studies are at a preliminary stage; however, some hydroxamate-based tracers such as the peptidomimetics [<sup>111</sup>In]-DTPA-RP782, [<sup>99m</sup>Tc]-(HYNIC-RP805)(tricine)(TPPTS), or Marimastat-ArB[<sup>18</sup>F]F<sub>3</sub> and the picolyl-benzenesulfonamide [<sup>123</sup>I]I-HO-CGS 27023A identified specifically the enzymatic action of MMPs in animal models of various pathologies. The development of new compounds that may lead to novel tracers (e.g. modification of zinc-binding group, variation of substituents attached to the S1', S2' and S3' pockets of the MMP inhibitors) and the use of antibodies and cell penetrating peptides are also discussed. In general, preclinical studies with atherosclerosis models proved to be more successful than those with oncological models.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1381-6128</s0></fA01><fA03 i2="1"><s0>Curr. pharm. des. : (Print)</s0></fA03><fA05><s2>19</s2></fA05><fA06><s2>25</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT</s1></fA08><fA11 i1="01" i2="1"><s1>MATUSIAK (Nathalie)</s1></fA11><fA11 i1="02" i2="1"><s1>VAN WAARDE (Aren)</s1></fA11><fA11 i1="03" i2="1"><s1>BISCHOFF (Rainer)</s1></fA11><fA11 i1="04" i2="1"><s1>OLTENFREITER (Ruth)</s1></fA11><fA11 i1="05" i2="1"><s1>VAN DE WIELE (Christophe)</s1></fA11><fA11 i1="06" i2="1"><s1>DIERCKX (Rudi A. J. O)</s1></fA11><fA11 i1="07" i2="1"><s1>ELSINGA (Philip H.)</s1></fA11><fA14 i1="01"><s1>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="02"><s1>Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Nuclear Medicine, University Hospital Ghent, University of Ghent</s1><s2>Ghent</s2><s3>BEL</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA20><s1>4647-4672</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>26320</s2><s5>354000506523540100</s5></fA43><fA44><s0>0000</s0><s1>© 2013 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>83 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>13-0258536</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Current pharmaceutical design : (Print)</s0></fA64><fA66 i1="01"><s0>ARE</s0></fA66><fC01 i1="01" l="ENG"><s0>Dysregulation of matrix metalloproteinase (MMP) activity can lead to a wide range of disease states such as atherosclerosis, inflammation or cancer. The ability to image MMP activity non-invasively in vivo, by radiolabelled synthetic inhibitors, would allow the characterization of atherosclerotic plaques, inflammatory lesions or tumors. Here we present an overview of radiolabelled MMP inhibitors (MMPIs) and MMP peptides for positron emission tomography (PET) and single photon emission computed tomography (SPECT) for the detection of proteolytic activity of MMPs. So far, most studies are at a preliminary stage; however, some hydroxamate-based tracers such as the peptidomimetics [<sup>111</sup>In]-DTPA-RP782, [<sup>99m</sup>Tc]-(HYNIC-RP805)(tricine)(TPPTS), or Marimastat-ArB[<sup>18</sup>F]F<sub>3</sub> and the picolyl-benzenesulfonamide [<sup>123</sup>I]I-HO-CGS 27023A identified specifically the enzymatic action of MMPs in animal models of various pathologies. The development of new compounds that may lead to novel tracers (e.g. modification of zinc-binding group, variation of substituents attached to the S1', S2' and S3' pockets of the MMP inhibitors) and the use of antibodies and cell penetrating peptides are also discussed. In general, preclinical studies with atherosclerosis models proved to be more successful than those with oncological models.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02T</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Méthode non invasive</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Non invasive method</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Método no invasivo</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Metalloendopeptidases</s0><s2>FE</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Metalloendopeptidases</s0><s2>FE</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Metalloendopeptidases</s0><s2>FE</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Cible</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Target</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Blanco</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Ciblage</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Targeting</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Blancado</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Tomographie par émission de positons</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Positron emission tomography</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Tomoscintigraphie émission monophotonique</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Single photon emission tomography</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tomografía emisión fotón único</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Produit radioisotopique</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Radioisotopic product</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Producto radioisotópico</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Peptide</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Peptides</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Péptido</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Article synthèse</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Review</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Artículo síntesis</s0><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Marquage radioisotopique</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Radiolabelling</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Marcación radioisotópica</s0><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Technétium 99mTc</s0><s2>NK</s2><s5>12</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Technetium 99mTc</s0><s2>NK</s2><s5>12</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Tecnecio 99mTc</s0><s2>NK</s2><s5>12</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Indium 111</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Iode 123</s0><s4>INC</s4><s5>87</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Fluor 18</s0><s4>INC</s4><s5>88</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Imagerie moléculaire</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Molecular imaging</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Exploration radioisotopique</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Radionuclide study</s0><s5>37</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Exploración radioisotópica</s0><s5>37</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Imagerie médicale</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Medical imagery</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Imaginería médica</s0><s5>38</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Imagerie fonctionnelle</s0><s5>39</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Functional imaging</s0><s5>39</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Imaginería funcional</s0><s5>39</s5></fC07><fN21><s1>245</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV3/Data/Main/Repository
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000656 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Repository/biblio.hfd -nk 000656 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV3
|flux= Main
|étape= Repository
|type= RBID
|clé= Pascal:13-0258536
|texte= Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT
}}
| This area was generated with Dilib version V0.5.77. |  |